ESCRS 2023: Thomas Bosshard discusses Oertli's 3-platform approach

News
Video

At this year's ESCRS meeting, we visited the Oertli Instruments booth, where co-CEO and co-owner Thomas Bosshard highlighted the company's 3-platform approach.

At this year's European Society of Cataract and Refractive Surgeons (ESCRS) meeting in Vienna, Austria, we visited the Oertli Instruments booth, where co-CEO and co-owner Thomas Bosshard highlighted the company's 3-platform approach. Here's our conversation, live from the congress floor.

Editor's note: This transcript has been edited for clarity.

Thomas Bosshard: Hey guys my name is Thomas, Thomas Bosshard. I'm the co-owner and CO-CEO of Oertli Instruments in Switzerland. We are proud to bring to the ESCRS, of course, our 3-platform strategy with the OS4, the CataRhex 3 and the Faros, which are highly renowned for super dynamic cataract surgery and vitrectomy surgery. With all its features, peripheral products and of course, along with it, our highly dynamic team, which is here for our customers and partners.

Probably the most interesting thing which we are currently featuring and getting more and more wild and exciting about is our Speed Mode with our with our CataRhex 3 and all our other platforms, which is a highly effective tool for safer and simpler surgery, whether it's in cataract or vitrectomy procedures.

In 2024, you should be excited about quite great pipeline which we are about to start early over the next few years which is to come. It's going to be a very interesting time from 2024 on, at and around Oertli Instruments.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.